NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Get Started
$19.12 -0.14 (-0.73 %)
(As of 03/21/2019 01:57 AM ET)
Previous Close$19.26
Today's Range$19.02 - $19.34
52-Week Range$17.42 - $24.97
Volume765,490 shs
Average Volume844,410 shs
Market Capitalization$13.15 billion
P/E Ratio17.38
Dividend Yield1.82%
Beta1.06
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRFS
Previous Symbol
CUSIPN/A
CIK1438569
Webwww.grifols.com
Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.30
Current Ratio2.77
Quick Ratio1.22

Price-To-Earnings

Trailing P/E Ratio17.38
Forward P/E Ratio16.34
P/E Growth1.37

Sales & Book Value

Annual Sales$5.30 billion
Price / Sales2.48
Cash Flow$1.4069 per share
Price / Cash Flow13.59
Book Value$8.07 per share
Price / Book2.37

Profitability

EPS (Most Recent Fiscal Year)$1.10
Net Income$704.63 million
Net Margins16.55%
Return on Equity18.32%
Return on Assets6.24%

Miscellaneous

Employees18,296
Outstanding Shares687,554,000
Market Cap$13.15 billion
Next Earnings DateN/A
OptionableOptionable

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a special dividend on Thursday, November 8th. Stockholders of record on Monday, December 3rd will be given a dividend of $0.2283 per share on Tuesday, December 11th. This represents a dividend yield of 2.25%. The ex-dividend date of this dividend is Friday, November 30th. This is an increase from GRIFOLS S A/S's previous special dividend of $0.01. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

Shares of GRIFOLS S A/S split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were issued to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

What price target have analysts set for GRFS?

6 brokers have issued twelve-month price targets for GRIFOLS S A/S's shares. Their forecasts range from $19.00 to $19.00. On average, they expect GRIFOLS S A/S's stock price to reach $19.00 in the next twelve months. This suggests that the stock has a possible downside of 0.6%. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

News stories about GRFS stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of GRIFOLS S A/S's key competitors?

What other stocks do shareholders of GRIFOLS S A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GRIFOLS S A/S investors own include Gilead Sciences (GILD), Allergan (AGN), Exxon Mobil (XOM), NVIDIA (NVDA), Nektar Therapeutics (NKTR), Celgene (CELG), Alibaba Group (BABA), Jazz Pharmaceuticals (JAZZ), Energy Transfer LP Unit (ET) and Biogen (BIIB).

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:
  • Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 55)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
  • Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 42)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (1.96%), AKO Capital LLP (1.79%), First Trust Advisors LP (0.68%), Bank of New York Mellon Corp (0.65%), Norges Bank (0.46%) and Millennium Management LLC (0.24%).

Which major investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Natixis Advisors L.P., Gladstone Capital Management LLP, Bank of New York Mellon Corp, FMR LLC, Great West Life Assurance Co. Can, Hsbc Holdings PLC, BlackRock Inc. and GABELLI & Co INVESTMENT ADVISERS INC..

Which major investors are buying GRIFOLS S A/S stock?

GRFS stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, AKO Capital LLP, Impax Asset Management Group plc, Millennium Management LLC, Two Sigma Investments LP, OLD Mission Capital LLC, Two Sigma Advisers LP and FNY Investment Advisers LLC.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $19.12.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $13.15 billion and generates $5.30 billion in revenue each year. The biotechnology company earns $704.63 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 18,296 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]


MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  302 (Vote Underperform)
Total Votes:  537
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Featured Article: What Are Cryptocurrencies?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel